medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2014, Number 3

<< Back Next >>

Residente 2014; 9 (3)

Síndrome metabólico en lupus eritematoso sistémico

Romero-Moreno JR, Ramírez-Villafaña M, González-Ponce F, Díaz-Rizo CV, Araújo-López A, Rodríguez-Hernández TM, Huerta-Viera M, González-López L

Language: Spanish
References: 35
Page: 116-123
PDF size: 233.50 Kb.


ABSTRACT

Metabolic syndrome (MS) is a condition characterized by the joint presence of obesity, dyslipidemia, resistance to insulin, and systemic arterial hypertension. Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by a chronic inflammatory process that may present multi-systemic complications. The main cause of death is related to cardiovascular disease. Patients with SLE have alterations in various components of the MS, including dyslipidemia, insulin resistance and higher rate of overweight/obesity. The increase in the frequency of MS in these patients is associated with pharmacological, immunological and inflammatory factors. The frequency of MS in them is from 25.6 to 86.6%. The treatments used in patients with MS in SLE are based on pharmacological management of antimalarial therapy, corticosteroids, immunosuppressives, antihypertensives, hypoglycemics and lipid-lowering and lifestyle modifications, including changes in eating habits and an increase in physical activity, since these are involved in the control of hyperglycemia, management of dyslipidemias and decrease in body weight.


REFERENCES

  1. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice. 2014; 2014 (1): 1-22.

  2. Wacher-Rodarte N. Epidemiología del síndrome metabólico. Gac Méd Méx. 2009; 145 (5): 384-391.

  3. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales.

  4. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285 (24): 86-97.

  5. Bello B, Sánchez G, Campos A, Báez E et al. Síndrome metabólico: un problema de salud con múltiples definiciones. Rev Méd Electrón. 2012; 34 (2): 199-213.

  6. Parker B, Urowitz MB, Gladman DD, Lunt M , Bae SC, Sanchez-Guerrero J et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013; 72: 1308-1314.

  7. Negrón AM, Molina MJ, Mayor AM, Rodriguez VE, Vilá LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008; 17 (4): 348-354.

  8. Curtis LG, Smith PB, Mendez-Fernandez YV, Wilhelm AJ, Musi Ye A, Major AS. Autoinmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus. Am J Physiol Endocrinol Metab. 2012; 303 (11): 313-324.

  9. Pereira J, Luna R, Gomes L, Duarte S, Leite L, da Trindade AK et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermarol. 2014; 89 (1): 118-125.

  10. Anaya JM, Shoenfeld Y, Cervera R. Systemic lupus erythematosus 2014. Autoimmune Diseases. 2014; 2014: 1-2.

  11. Peláez- Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyel J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. The Journal of Rheumatology. 2011; 38 (86): 3-8.

  12. Enríquez-Mejía MG. Fisiopatología del lupus eritematoso sistémico. Revista de Medicina e Investigación. 2013; 1 (1): 8-16.

  13. Morales-Romero J, Cázares-Méndez JM, Gámez-Nava JI, Triano-Páez M et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1 (2): 87-94.

  14. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010; 36 (1): 81-97.

  15. El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al. Hyperinsulinemia, insulin resistance, and circulcating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006; 33 (1): 50-56.

  16. Wijaya LK, Kaskmir YI, Sukmana N, Subetki I et al. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones-Indones J Intern Med. 2005; 37 (3): 132-144.

  17. Cadaval RAM, Martinez JE, Mazzolin MA, Barros RGT et al. Assessment of the risk of coronary heart disease in women with systemic lupus erythematosus. Bras J Rheumatol. 2009; 49 (6): 658-669.

  18. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66: 208-214.

  19. Toloza S, Uribe A, McGwin G, Alarcon G, Fessler B, Bastian H et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Arthritis & Rheumatism. 2004; 50 (12): 3947-3957.

  20. Ormseth MJ, Swift LL, Fazio S, Linton MF, Raggi P, Solus JF et al. Free fatty acids are associated with metabolic syndrome and insulin resistance, but not inflammation in SLE patients. Lupus. 2013; 22 (1): 26-33.

  21. Oeser A, Chung CP, Ananuma Y, Avalos I, Stein M. Obesity is an independent contributor functional capacity and inflammation in systemic lupus erythematosus. Arthritis & Rheumatism. 2005; 52 (11): 3651-3659.

  22. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008; 58 (7): 2105-2112.

  23. Parker B, Ahmad Y, Sherlmerdine J, Edlin H, Yates AP, Teh L et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus. 2011; 20: 1459-1465.

  24. Pagano G, Bruno A, Cavallo-Perin P, Cesco L, Imbimbo B. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone. Arch Intern Med. 1989; 149 (5): 1089-1101.

  25. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relatioship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002; 40 (1): 937-943.

  26. Shinjo SK, Bonfa E, Wojdyla D, Borba EF et al. Antimalarial treatment may have a time- dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010; 62: 855-862.

  27. VanHalm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther. 2006; 8: R151.

  28. Maiz A. El síndrome metabólico y riesgo cardiovascular. Boletín de la Escuela de Medicina. 2005; 30 (1): 1-6.

  29. Escott-Stump S. Nutrición, diagnóstico y tratamiento. 6a ed. Wolters Kluwer: Lippincott Williams & Wilkins; 2008.

  30. Minami Y. Diet and systemic lupus erythematosus: a 4 year prospective study Japanese patients. J Rheumatol. 2003; 30: 747.

  31. Shah M. Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program. J Rheumatol. 2004; 31: 71.

  32. Simopoulos A. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21: 495.

  33. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk Factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93 (5): 513-519.

  34. Rhaman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001; 10(2): 93-96.

  35. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005; 14 (9): 683-686.




2020     |     www.medigraphic.com